ITUS Corporation (NYSE:ANIX) rose 6.7% during trading on Thursday . The company traded as high as $2.94 and last traded at $2.85, approximately 459,887 shares were traded during trading. An increase of 93% from the average daily volume of 238,614 shares. The stock had previously closed at $2.67.

ANIX has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded ITUS from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Thursday, May 21st. Aegis reissued a “buy” rating on shares of ITUS in a report on Tuesday, June 2nd.

The business has a fifty day moving average of $2.78 and a 200 day moving average of $2.56.

ITUS (NYSE:ANIX) last announced its earnings results on Tuesday, June 9th. The company reported ($0.12) EPS for the quarter.

In other news, CEO Amit Kumar purchased 20,000 shares of ITUS stock in a transaction that occurred on Friday, June 12th. The shares were bought at an average cost of $2.03 per share, with a total value of $40,600.00. Following the completion of the purchase, the chief executive officer now directly owns 234,000 shares in the company, valued at $475,020. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lewis H. Titterton, Jr. bought 31,083 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was bought at an average cost of $2.35 per share, for a total transaction of $73,045.05. Following the completion of the purchase, the director now owns 955,826 shares of the company’s stock, valued at approximately $2,246,191.10. The disclosure for this purchase can be found here.

ITUS Company Profile (NYSE:ANIX)

Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.

Further Reading: Why does the United States have a lingering trade deficit?

Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.